Form 4: Teladoc Health CEO Converts Restricted Stock Units to Common Shares

Teladoc Health, Inc. CEO Charles Divita III reported the conversion of 156,641 restricted stock units into common shares, a routine transaction related to his compensation.

Summary

• Charles Divita III, the Chief Executive Officer and a Director of Teladoc Health, Inc. (TDOC), filed a Form 4 reporting a change in his beneficial ownership.
• On June 10, 2025, Mr. Divita acquired 156,641 shares of Teladoc Health common stock.
• This acquisition resulted from the conversion of 156,641 restricted stock units (RSUs) into common stock on a one-for-one basis.
• The original grant of 469,924 restricted stock units occurred on June 10, 2024, with a vesting schedule of one-third on the first anniversary of the grant date, and the remainder vesting in eight substantially equal quarterly installments thereafter.
• Following this reported transaction, Mr. Divita directly beneficially owns 156,641 shares of Teladoc Health common stock and 313,283 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine compensation-related transaction, indicating the CEO is receiving vested equity, which is a positive for executive retention and alignment of interests with shareholders. No negative implications are present.

Positives

• The conversion of restricted stock units into common shares represents a routine vesting event, which is a standard component of executive compensation and retention strategies.
• The CEO's continued direct beneficial ownership of common shares and a significant number of remaining RSUs aligns his financial interests with those of the company's shareholders.

Negatives

• No specific negative points or adverse events are identified within this routine ownership change filing.

Risks

• The document itself does not detail specific company-wide risks, but the value of the acquired common shares and the remaining restricted stock units is inherently subject to the market risks associated with Teladoc Health's stock performance and broader market conditions.

Future Outlook

The remaining 313,283 restricted stock units held by Charles Divita III are scheduled to vest in eight substantially equal quarterly installments following the first anniversary of the June 10, 2024 grant date.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity transaction, which is a common regulatory requirement across all publicly traded companies. It does not provide specific insights into broader industry trends within the telehealth or healthcare technology sectors.

Related Party Transactions

• The transaction involves the conversion of restricted stock units granted by Teladoc Health, Inc. to its Chief Executive Officer, Charles Divita III. This is a standard compensation-related related party transaction.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive compensation and ownership. The transaction itself is a routine vesting and conversion and is not typically considered a significant catalyst for share price movement unless it signals an immediate intent to sell (which is not indicated here).
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• Future vesting of the remaining 313,283 restricted stock units in eight substantially equal quarterly installments as per the original grant terms.

Key Dates

Keywords

Teladoc Health, TDOC, Form 4, Insider Trading, Restricted Stock Units, RSU Conversion, Executive Compensation, Charles Divita III, Beneficial Ownership